SCHEMBL4950895

SCHEMBL4950895

CCc1nnsc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ABCC8 Q09428 19/20 0.47
KCNJ11 Q14654 19/20 0.47
GAA P10253 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tert-Butylamine SCHEMBL4952237 0.93 ABCC8 (0.43) ABCC8KCNJ11GAA
SCHEMBL4953112 0.80 ABCC8 (0.48) ABCC8KCNJ11
SCHEMBL593650 0.72 KDM4E (0.43) ABCC8KCNJ11GAA
SCHEMBL452517 0.71
Hydrochloric Acid SCHEMBL6602988 0.70 LMNA (0.51) GAA
SCHEMBL2212373 0.69 ALDH1A1 (0.52) GAATDP1
SCHEMBL5717545 0.67 ABCC8 (0.41) ABCC8KCNJ11GAATDP1
SCHEMBL28872781 0.67 ALDH1A1 (0.46)
SCHEMBL8550625 0.66 ABCC8 (0.34) ABCC8KCNJ11
SCHEMBL13480534 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-8325110-A None JP disclosed
EP-4578451-A2 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS Novartis AG (CH) 2025-07-02 EP disclosed
EP-4214210-B1 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS NOVARTIS AG (CH) 2025-04-09 EP disclosed
US-20240383856-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-11-21 US disclosed
EP-4192814-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-08-07 EP disclosed
CN-117616011-A Inhibitors of transglutaminase 策迪拉有限公司 2024-02-27 CN disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 US disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 US disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 US disclosed
EP-4192814-A1 INHIBITORS OF TRANSGLUTAMINASES Zedira GmbH (DE) 2023-06-14 EP disclosed
EP-1688041-A1 An agricultural and horticultural disease controller and a method for controlling the diseases Nihon Nohyaku Co., Ltd. (JP) 2006-08-09 EP disclosed
EP-0824317-B1 AN AGRICULTURAL AND HORTICULTURAL DISEASE CONTROLLER AND A METHOD FOR CONTROLLING THE DISEASES NIHON NOHYAKU CO LTD (JP) 2004-10-13 EP disclosed
CN-1163139-C Agricultural and horticultural disease controller and method for controlling diseases �ձ��ݶ�ũҩ��ʽ���� 2004-08-25 CN disclosed
EP-1413199-A1 An agricultural and horticultural disease controller and a method for controlling the diseases Nihon Nohyaku Co., Ltd. (JP) 2004-04-28 EP disclosed
US-6521649-B1 1,2,3-thiadiazole derivatives; expanding spectrum of controllable diseases and period of time when effective applications are possible; reducing dosage NIHON NOHAYKU CO., LTD. (JP) 2003-02-18 US disclosed
US-6166054-A Agricultural and horticultural disease controller and a method for controlling the diseases NIHON NOHYAKU CO., LTD. (JP) 2000-12-26 US disclosed
CN-1180297-A Agricultural and horticultural disease control agent and method for controlling these diseases NIHON NOHYAKU CO LTD (JP) 1998-04-29 CN disclosed
EP-0824317-A2 AN AGRICULTURAL AND HORTICULTURAL DISEASE CONTROLLER AND A METHOD FOR CONTROLLING THE DISEASES Nihon Nohyaku Co., Ltd. (JP) 1998-02-25 EP disclosed
JP-H08325110-A CONTROLLER FOR AGRICULTURAL AND HORTICULTURAL DISEASE DAMAGE AND ITS USE NIPPON NOHYAKU CO LTD 1996-12-10 JP disclosed
WO-1996029871-A2 AN AGRICULTURAL AND HORTICULTURAL DISEASE CONTROLLER AND A METHOD FOR CONTROLLING THE DISEASES NIHON NOHYAKU CO., LTD. (JP) 1996-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS SPPL2A, SPPL2B, BACE1 ABCC8 1044/4885KCNJ11 4745/4885GAA 2507/4885
US-20240383856-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 ABCC8 3519/4885KCNJ11 4191/4885GAA 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.